Nature | Vol 585 | 24 September 2020 | E21Corrections & amendments
Publisher Correction:
The National Lung Matrix
Trial of personalized
therapy in lung cancer
https://doi.org/10.1038/s41586-020-2656-3
Correction to: Nature https://doi.org/10.1038/s41586-020-2481-8
Published online 15 July 2020
Check for updatesGary Middleton, Peter Fletcher, Sanjay Popat, Joshua Savage,
Yvonne Summers, Alastair Greystoke, David Gilligan, Judith Cave,
Noelle O’Rourke, Alison Brewster, Elizabeth Toy, James Spicer, Pooja
Jain, Adam Dangoor, Melanie Mackean, Martin Forster, Amanda
Farley, Dee Wherton, Manita Mehmi, Rowena Sharpe, Tara C. Mills,
Maria Antonietta Cerone, Timothy A. Yap, Thomas B. K. Watkins,
Emilia Lim, Charles Swanton & Lucinda Billingham
In this Article, the description for the Supplementary Information file
stated: “This file contains Pre-clinical rationale for triaging participants
to genotype-matched targeted therapies in the NLMT.”. However, the
initial Supplementary Information file uploaded contained only the
trial protocol and did not contain the rationale. The Supplementary
Information file has now been replaced online, and the description
has been updated to read: “This file contains pre-clinical rationale for
triaging participants to genotype-matched targeted therapies in the
NLMT and Protocol version 8.0, in use on 30 November 2019.”.
In addition, the first four sentences of the Acknowledgements sec-
tion have been altered to read: ‘The Investigators and Sponsor thank
all the patients and their families who participated in this trial, as well
as the NHS Trusts and staff and the members of the Trial Steering Com-
mittee, chaired by R. Kaplan and including independent members
K. Kerr, C. Dick, J. Paul and J. Wason, who supported this trial. We thank
our patient and public representatives, M. Baker on the Trial Steering
Committee and T. Haswell on the Trial Management Group. We are
grateful for the support of the Trial Management Group, including
G. Cook, A. Desai, A. Devaraj, D. Fennell, M. Griffiths, S. Janes,
S. M. Lee, U. McDermott, A. Nicholson, P. Rehal, S. Subramaniam,
P. Taniere, Y. Wallis and D. White and for the support of principal
investigators P. Shaw (Velindre Cancer Centre), C. Lewanski and
D. Power (Imperial College Healthcare NHS Trust) and S. Danson
(Weston Park Cancer Centre). We thank all staff at the Cancer
Research UK Clinical Trials Unit for their contributions to the trial,
including A. Allen, K. Brock, L. Crack, K. Davies, K. James, S. Mee,
I. Nutt and S. Ordish.